"Cibus is an excellent strategic fit for Calyxt given our complementary technology platforms, and the merger provides a great opportunity to leverage multiple synergies to drive innovation and shareholder value," said CEO Michael Carr. "I am deeply proud of the significant accomplishments made by our team and their commitment to further the science of biotechnology and synthetic biology in significant ways."
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CLXT:
- Calyxt Reports Fourth Quarter 2022 Financial Results and Provides Corporate Update
- Calyxt files Form S-4 in connection with merger with Cibus Global
- Calyxt, Inc. Announces its Filing of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC
- Calyxt downgraded to Hold from Buy at Canaccord
- Calyxt More than Doubles on Cibus Deal